The National Institute of Public Health (INSP) in Mexico, led by Dr. Eduardo Lazcano Ponce, recently held a meeting with executives from Grupo PiSA to discuss collaboration on enhancing clinical research and pharmaceutical training. This initiative aims to strengthen public health in Mexico through scientific development and specialized training in pharmacological treatments. Representatives from both organizations highlighted the importance of working together to advance clinical research and improve health outcomes.

During the meeting, various joint initiatives were presented, focusing on the scientific activities of the INSP, as well as its infrastructure and technical capabilities. By identifying strategic areas for development, both parties aim to enhance the dissemination of medical and pharmaceutical knowledge across the country. The collaboration seeks to bolster Mexico's position in the field of clinical research and promote local advancements in public health.

This partnership between the INSP and Grupo PiSA underscores the growing recognition of the importance of homegrown clinical research in Mexico. With increasing investment in local training and scientific initiatives, this endeavor is expected to yield significant benefits for public health management and pharmaceutical innovation, reflecting a broader trend of valuing domestic research capabilities.